94 search results for: Atopic Dermatitis
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.
World Atopic Eczema Day 2024 | 14 September
In recognition of World Atopic Eczema Day 2024, ADVENT is providing medical education resources to increase the awareness of atopic dermatitis (AD).
The Growing Burden: Cumulative Disease Impact and Comorbidities in Pediatric AD
Dr. Yu and Dr. Wine Lee discuss the clinical presentation and burden of atopic dermatitis, the role of type 2 inflammation in the development of atopic comorbidities, and the importance of early intervention in potentially preventing cumulative life course impairment in AD at PeDRA 2025.
Exploring the Potential Disease-Modifying Approaches in AD
Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.
The Burden of AD: More Than Skin Deep
Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.
ADVENT at WCPD 2025
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
Misconception on AD Pathomechanisms
Dr. Jason Hawkes provides key pathophysiologic insights and debunks common misconceptions surrounding atopic dermatitis.
AD: Challenging the Conventional Narrative
Dr. Ahuva Cices provides key pathophysiologic insights and dispels common misconceptions surrounding atopic dermatitis.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
The Type 2 Inflammatory Link in AD, CSU, and PN
Dr. Jason Hawkes explores the unique clinical manifestations of atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis, while highlighting the shared role of type 2 inflammation across these distinct diseases.
